Treatments that target a fragment of the mutant protein that causes Huntington’s disease might be more effective than treatments—now in clinical trials—that target the whole protein but leave this fragment intact, a new study in mice suggests. The findings appear in Science Translational Medicine.
This article was originally published on MedicalXpress.com

